In the last trading session, 0.49 million Rigel Pharmaceuticals (NASDAQ:RIGL) shares changed hands as the company’s beta touched 1.28. With the company’s per share price at $16.44 changed hands at -$0.71 or -4.14% during last session, the market valuation stood at $289.59M. RIGL’s last price was a discount, traded about -81.39% off its 52-week high of $29.82. The share price had its 52-week low at $7.48, which suggests the last value was 54.5% up since then. When we look at Rigel Pharmaceuticals’s average trading volume, we note the 10-day average is 0.23 million shares, with the 3-month average coming to 231.71K.

Analysts gave the Rigel Pharmaceuticals (RIGL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RIGL as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Rigel Pharmaceuticals’s EPS for the current quarter is expected to be 0.33.

Rigel Pharmaceuticals (NASDAQ:RIGL) trade information

Instantly RIGL was in red as seen at the end of in last trading. With action -10.89%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 13.38%, with the 5-day performance at -10.89% in the red. However, in the 30-day time frame, Rigel Pharmaceuticals (NASDAQ:RIGL) is -36.87% down. Looking at the short shares, we see there were 0.47 million shares sold at short interest cover period of 1.69 days.

The consensus price target for the stock as assigned by Wall Street analysts is 1.5, meaning bulls need a downside of -996.0% from its current market value. According to analyst projections, RIGL’s forecast low is 1 with 2 as the target high. To hit the forecast high, the stock’s price needs a 87.83% surge from its current level, while the stock would need to tank 93.92% for it to hit the projected low.

Rigel Pharmaceuticals (RIGL) estimates and forecasts

Data shows that the Rigel Pharmaceuticals share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 108.07% over the past 6 months, a 112.14% in annual growth rate that is considerably higher than the industry average of 16.40%. Year-over-year growth is forecast to reach 44.68% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 47.42M. 2 analysts are of the opinion that Rigel Pharmaceuticals’s revenue for the current quarter will be 43.49M. The company’s revenue for the corresponding quarters a year ago was 35.79M and 29.53M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 32.49%. The estimates for the next quarter sales put growth at 47.26%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.96%. The 2024 estimates are for Rigel Pharmaceuticals earnings to increase by 120.53%.

RIGL Dividends

Rigel Pharmaceuticals is expected to release its next quarterly earnings report in January.

Rigel Pharmaceuticals (NASDAQ:RIGL)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 2.18% of Rigel Pharmaceuticals shares while 68.01% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 69.53%. There are 68.01% institutions holding the Rigel Pharmaceuticals stock share, with BARCLAYS PLC the top institutional holder. As of 2024-06-30, the company held 0.006% of the shares, roughly 10573.0 RIGL shares worth $88000.0.

IFP ADVISORS, INC holds the second largest percentage of outstanding shares, with 0.0006% or 1000.0 shares worth $807.0 as of 2024-06-30.